Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK | Market Cap | 21.82B -24.8% |
| Revenue (ttm) | 9.21B +14,598.9% |
| Net Income | 6.46B |
| EPS | 90.22 |
| Shares Out | 70.62M |
| PE Ratio | 3.42 |
| Forward PE | 17.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,360 |
| Average Volume | 314,725 |
| Open | 309.00 |
| Previous Close | 309.00 |
| Day's Range | 300.30 - 309.30 |
| 52-Week Range | 233.50 - 556.00 |
| Beta | 0.57 |
| RSI | 47.91 |
| Earnings Date | May 7, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
Financial StatementsNews
Zealand Pharma Announces Positive Topline Phase 3 Results For Weight-Loss Drug Survodutide
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, announced on Tuesday that Boehringer Ingelheim reported promising topline results from the Phase 3 SYNCHRONIZE-1 trial for Survodutid...
Zealand Pharma Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline targeting obesity and metabolic diseases, with Petrelintide showing strong efficacy and tolerability, and Survodutide poised for major phase III data this year. Strategic partnerships, financial strength, and upcoming clinical milestones position the company for significant growth.
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Zealand Pharma slump wipes billions off its value after obesity drug data disappoints
Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity drug petrelintide fe...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma Transcript: Study result
Petrelintide achieved sustained double-digit weight loss with a placebo-like safety profile in the phase II ZUPREME-1 trial, showing strong efficacy across doses and exceptional tolerability. These results support its advancement to phase III as a foundational therapy for chronic weight management.
Zealand Pharma Earnings Call Transcript: Q4 2025
2025 saw record revenue and profit, driven by the Roche partnership and strong R&D investment. Key obesity and metabolic assets, petrelintide and survodutide, are advancing with major clinical milestones expected in 2026, supported by a robust cash position.
Zealand Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ambitious plans target obesity and metabolic diseases, with major clinical milestones for petrelintide and Survodutide expected in 2024. Strategic partnerships with Roche and Boehringer Ingelheim support a robust pipeline, aiming for five product launches in five years and significant investment in research.
Zealand Pharma Transcript: CMD 2025
Ambitious plans target redefining obesity management with petrelintide as a foundational therapy, a fivefold increase in research investment, and five launches by 2030. Strategic partnerships, robust clinical programs, and a focus on patient experience and tolerability underpin the vision to become a generational biotech.
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research as it seeks to differentiate its experimental obesity drug candidates in an increasingly competiti...
Zealand Pharma Transcript: Jefferies London Healthcare Conference 2025
A novel obesity treatment strategy is being advanced through a key partnership, with petrelintide positioned for strong differentiation based on tolerability and efficacy. The company is leveraging its R&D strengths and capital to expand its pipeline and commercial presence, with major data readouts and strategic updates expected soon.
Zealand Pharma Earnings Call Transcript: Q3 2025
Strong progress in obesity drug pipeline with key phase 2 and 3 milestones, robust financials driven by Roche partnership, and a sharpened focus on high-impact assets. Guidance narrowed as dapiglutide development is paused, with significant cash reserves supporting future innovation.
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an...
Zealand Pharma Transcript: Bank of America Global Healthcare Conference 2025
A major partnership is advancing key assets toward late-stage trials, with a focus on obesity and rare diseases. Petrelintide is positioned for strong efficacy and tolerability, with flexible dosing strategies and a representative trial population. Regulatory and market trends favor double-digit weight loss and functional outcomes.
Zealand Pharma may sell future obesity drug direct to patients, amid market shifts
Zealand Pharma is considering a direct-to-patient sales model for its experimental weight-loss drug alongside traditional insurer channels, its CEO told Reuters in an interview on Monday, citing shift...
Zealand Pharma Transcript: Cantor Global Healthcare Conference 2025
Ambitious growth in the obesity market is driven by differentiated amylin and GLP-1 assets, strategic partnership with Roche, and a focus on patient experience and adherence. Key clinical readouts and an R&D event are expected to shape the next phase of innovation and expansion.
Zealand Pharma Earnings Call Transcript: Q2 2025
Strong H1 2025 results driven by Roche partnership, with DKK 9.1B revenue and DKK 16.6B cash. Obesity pipeline advances with petrelintide and survodutide nearing key data, while robust financials support continued R&D and strategic partnerships.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Zealand Pharma Obesity Therapy Shows Positive Trial Results
Zealand Pharma said its obesity treatment dapiglutide showed positive topline results in its latest trial, demonstrating its further potential for weight loss and to treat obesity-related comorbiditie...
Zealand Pharma Transcript: 46th Goldman Sachs Annual Global Healthcare Conference
Significant progress was made with Petrelintide, including a major partnership with Roche and expanded leadership to support growth. The company is advancing late-stage trials, targeting durable weight loss and differentiation in the obesity market, while maintaining a strong financial outlook.
European stocks recover after Trump delays EU tariffs in hopes of deal
European shares kicked off the week on a positive note on Monday, recouping the previous session's losses, as markets heaved a sigh of relief after U.S. President Donald Trump delayed his threat to im...
Zealand Pharma Transcript: Bank of America Global Healthcare Conference
A major partnership with Roche brings significant capital and shared development for obesity therapies, with petrelintide and other assets advancing through late-stage trials. The pipeline is robust, with key data and regulatory milestones expected over the next year.
Zealand Pharma Earnings Call Transcript: Q1 2025
Entered a transformative Roche partnership, securing strong financials and advancing a robust obesity pipeline. Key clinical trials in obesity and rare diseases are progressing, with major data readouts and financial milestones expected in the next year.
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives a...